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Abstract
Background: Children who have suffered from critical illnesses that required treatment in a paediatric intensive
care unit (PICU) have long-term physical and neurodevelopmental impairments. The mechanisms underlying this
legacy remain largely unknown. In patients suffering from chronic diseases hallmarked by inflammation and
oxidative stress, poor long-term outcome has been associated with shorter telomeres. Shortened telomeres have
also been reported to result from excessive food consumption and/or unhealthy nutrition. We investigated whether
critically ill children admitted to the PICU have shorter-than-normal telomeres, and whether early parenteral
nutrition (PN) independently affects telomere length when adjusting for known determinants of telomere length.
Methods: Telomere length was quantified in leukocyte DNA from 342 healthy children and from 1148 patients
who had been enrolled in the multicenter, randomised controlled trial (RCT), PEPaNIC. These patients were
randomly allocated to initiation of PN within 24 h (early PN) or to withholding PN for one week in PICU (late PN).
The impact of early PN versus late PN on the change in telomere length from the first to last PICU-day was
investigated with multivariable linear regression analyses.
Results: Leukocyte telomeres were 6% shorter than normal upon PICU admission (median 1.625 (IQR 1.446–1.825)
telomere/single-copy-gene ratio (T/S) units vs. 1.727 (1.547–1.915) T/S-units in healthy children (P < 0.0001)).
Adjusted for potential baseline determinants and leukocyte composition, early PN was associated with telomere
shortening during PICU stay as compared with late PN (estimate early versus late PN –0.021 T/S-units, 95% CI −0.
038; 0.004, P = 0.01). Other independent determinants of telomere length identified in this model were age,
gender, baseline telomere length and fraction of neutrophils in the sample from which the DNA was extracted.
Telomere shortening with early PN was independent of post-randomisation factors affected by early PN, including
longer length of PICU stay, larger amounts of insulin and higher risk of infection.
Conclusions: Shorter than normal leukocyte telomeres are present in critically ill children admitted to the PICU.
Early initiation of PN further shortened telomeres, an effect that was independent of other determinants. Whether
such telomere-shortening predisposes to long-term consequences of paediatric critical illness should be further
investigated in a prospective follow-up study.
Trial registration: ClinicalTrials.gov, NCT01536275. Registered on 16 February 2012.
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Children
* Correspondence: greet.vandenberghe@med.kuleuven.be
†Equal contributors
1Clinical Division and Laboratory of Intensive Care Medicine, Department of
Cellular and Molecular Medicine, Herestraat 49, B-3000 Leuven, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Verstraete et al. Critical Care  (2018) 22:38 
https://doi.org/10.1186/s13054-018-1972-6
Background
Survival of children who require treatment in the paediat-
ric intensive care unit (PICU) for life-threatening diseases,
extensive surgery, or trauma has improved [1, 2]. How-
ever, PICU survivors continue to suffer from an important
long-term legacy of critical illness, characterised by im-
paired physical and neurocognitive development [3]. This
legacy could be explained by the pre-admission disease [4]
or be induced or aggravated by the acute event and/or the
intensive medical care. Whether alterations in telomere
length could play a role has not been investigated.
Telomeres are nucleoprotein complexes at the ter-
mini of eukaryote chromosomes that protect chromo-
some ends from degradation and prevent fusion with
neighbouring chromosomes [5]. Telomeres shorten
with each cell cycle [6], making them good markers of
overall cellular replicative capacity and senescence [7].
This telomere shortening process can be accelerated
by environmental and lifestyle factors, many of which
increase oxidative stress levels and inflammation, such
as smoking, life stress and exposure to air pollution
[7–9]. Furthermore, shorter telomeres have been re-
ported in leukocyte DNA from children with chronic
medical conditions [10, 11], possibly due to more cell
replication cycles in immune cells, which has been
associated with long-term metabolic and cardiovascu-
lar morbidity and mortality [12, 13]. Interestingly, evi-
dence suggests that macronutrient restriction and/or
healthy feeding habits may slow down the progressive
shortening of telomeres, which could protect against
age-related diseases [14, 15].
Whether critically ill children are admitted to the
PICU with shorter telomeres reflecting the premorbid
state is unknown. Also, it remains unknown whether
the use of parenteral nutrition (PN) early during critical
illness in children, or instead accepting a substantial
macronutrient deficit when only relying on enteral
feeds that often fail in such patients, affects leukocyte
telomere length.
As critically ill children often suffer from an underlying
chronic disease or are admitted to the PICU after an insult
characterised by hypoxia or inflammation, we hypothe-
sised that leukocyte telomeres in critically ill children
upon PICU admission are shorter than those of matched
healthy children. Also, as previous studies performed in
rodent models and in disease-free adults have suggested
shortened telomeres as the result of excessive food con-
sumption [14, 15], we further hypothesised that initiation
of supplemental PN given early during critical illness, as
compared with not using PN for one week in the PICU,
an intervention that has been shown to slow down rather
than accelerate recovery, could further shorten telomeres
by the time of PICU discharge, directly or indirectly via its
slowing effect on recovery [2, 16].
Methods
Study population
This pre-planned secondary analysis included 1148 critic-
ally ill children (0–17 years), enrolled in a randomised
controlled trial on macronutrient management in PICU
(PEPaNIC-study, N = 1440) [2] and 342 healthy children,
from whom leukocyte DNA was available (Fig. 1, Table 1).
Patients had been randomised to early initiation of PN
supplementing insufficient enteral nutrition to reach the
caloric target within 48 h (early PN), or to postponing any
PN to beyond the first week in PICU if enteral nutrition
was still insufficient (late PN).
For the full study protocol, we refer to the original
article and electronic supplementary protocol [2, 17].
The institutional ethical review boards of the centres in
Leuven (ML8052), Rotterdam (NL38772.000.12) and
Edmonton (Pro00038098) approved the study, which
was performed in accordance with the 1975 Declar-
ation of Helsinki as revised in 1983. Written informed
consent for participation in the trial, blood sampling
and data analyses was obtained from the parents or
legal guardians.
Leukocyte telomere length measurements
Patient blood samples were collected upon PICU admis-
sion and on the last PICU day. For comparison, blood
was sampled from 342 healthy children who had never
been admitted to a PICU, immediately after intravenous
catheterisation prior to minor elective surgery (Fig. 1,
Table 1). Relative telomere length in leukocyte DNA was
quantified as telomere/single-copy-gene (T/S) ratio (pro-
portional to average telomere length in a cell [18]) with
quantitative PCR in the laboratory of Prof. Elizabeth
Blackburn (Additional file 1) [19].
1440 patients in 
study population
1148 patients 
assessed for 
telomere length
326 patients
326 healthy children
for comparison
of telomere length
292 excluded 
because of no DNA
342 healthy children 
assessed for 
telomere length
propensity
score 
matching
644 patients with 
neutrophil count 
available for 
multivariable analyses
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow
diagram of the study participants
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Table 1 Demographics
Total population Subgroup with neutrophil
count available
Matched subgroupsa
Baseline characteristics PICU patients
N = 1148
PICU patients
N = 644
PICU patients
N = 326
Healthy children
N = 326
Male sex, N (%) 640 (55.7) 355 (55.1) 180 (55.2) 179 (54.9)
Age (years) 1.8 (0.3–7.4) 1.6 (0.3–5.9) 4.5 (1.7–8.7) 4.5 (1.8–7.8)
Age <1 year, N (%) 476 (41.5) 276 (42.9) 51 (15.6) 44 (13.5)
Height (%)b 38.7 (8.5–78.2) 35.1 (7.8–71.5) 38.1 (8.5–78.4)
Weight (%)b 32.5 (8.3–67.8) 29.8 (6.5–62.2) 39.8 (14.8–70.0)
Chronicity, N (%)c 882 (76.8) 532 (82.6) 242 (74.2)
Randomisation to late PN, N (%) 576 (50.2) 324 (50.3) 167 (51.2)
STRONGkids risk level, N (%)d
Medium 1046 (91.1) 605 (93.9) 299 (91.7)
High 102 (8.9) 39 (6.1) 27 (8.3)
PeLOD score first 24 he 22 (12–32) 31 (21–32) 21 (11–31)
PIM2 scoref −2.7 (−3.6; –1.4) −3.0 (−3.7; –1.7) −2.7 (−3.8; –1.5)
PIM2 probability of death (%)g 6.3 (2.6–19.3) 5.0 (2.4–15.5) 6.5 (2.6–22.0)
Emergency admission, N (%) 554 (48.3) 218 (33.9) 159 (48.8)
Diagnostic category, N (%)
Surgical
Abdominal 51 (4.4) 19 (3.0) 7 (2.2)
Burns 8 (0.7) 1 (0.2) 4 (1.2)
Cardiac 517 (45.0) 377 (58.5) 128 (39.3)
Neurosurgery-traumatic brain injury 106 (9.2) 51 (7.9) 40 (12.3)
Thoracic 46 (4.0) 29 (4.5) 11 (3.4)
Transplantation 22 (1.9) 6 (0.9) 7 (2.2)
Orthopaedic surgery-trauma 50 (4.4) 32 (5.0) 18 (5.5)
Other 31 (2.7) 13 (2.0) 13 (4.0)
Medical
Cardiac 44 (3.8) 13 (2.0) 15 (4.6)
Gastrointestinal-hepatic 5 (0.4) 4 (0.6) 4 (1.2)
Oncologic-hematologic 11 (1.0) 0 (0.0) 5 (1.5)
Neurologic 77 (6.7) 33 (5.1) 19 (5.8)
Renal 1 (0.1) 0 (0.0) 1 (0.3)
Respiratory 116 (10.1) 38 (5.9) 26 (8.0)
Other 63 (5.5) 28 (4.3) 28 (8.6)
Condition on admission
Mechanical ventilation required, N (%) 1033 (90.0) 580 (90.1) 286 (87.7)
ECMO or other assist device, required, N (%) 40 (3.5) 14 (2.2) 9 (2.8)
Infection, N (%) 415 (36.1) 173 (26.9) 116 (35.6)
Data are expressed as number (%) or median (IQR)
STRONGkids Screening Tool for Risk on Nutritional Status and Growth, PeLOD Paediatric Logistic Organ Dysfunction, PIM2 Paediatric Index of Mortality 2, ECMO
extracorporeal membrane oxygenation, PICU paediatric intensive care unit
aThere were no significant differences in sex, age, and number of infants between matched subgroups of patients and controls
bHeight and weight, expressed as percentiles of population norms, were calculated with the anthropometric calculators for normal children, based on the World
Health Organisation Growth Charts for Canada (version 2015/02/24), and for children with syndromes known to affect height and weight (version 2014/09/25).
Patients and healthy children were not matched for height and weight, as a growth delay is expected in critically ill children
cDichotomizing label indicating whether or not the patient was suffering from any symptomatic chronic disease identified through screening of the patient’s
medical history and hospital files
dScores on the STRONGkids range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1–3 indicating medium risk, and a score of 4–5 indicating high risk
ePeLOD scores range from 0 to 71, with higher scores indicating more severe illness
fPIM2 scores, with higher scores indicating a higher risk of mortality
gPIM2 probability of death, ranging from 0% to 100%, with higher percentages indicating a higher probability of death in PICU
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Statistical analyses
Data are presented as mean and standard error (SE) or
95% confidence interval (CI), median and interquartile
range (IQR), or number and proportion, as appropriate.
Univariate comparisons were performed with the chi-
square (Fisher exact) test for proportions, and with the
Wilcoxon rank-sum or Student t test depending on the
type of distribution of continuous data.
For comparing leukocyte telomere lengths of critically ill
patients with those of healthy children, given that age, sex,
and environment affect telomere length [20, 21], we se-
lected demographically comparable cohorts of patients and
controls via propensity-score matching with age, sex and
treatment centre as covariates, yielding 326 critically ill and
326 healthy children (Fig. 1, Table 1, Additional file 1).
The impact of early PN, as compared with late PN, on
the change in leukocyte telomere length from admission
to the last PICU day was first assessed in a univariate
way for the total number of patients for whom leukocyte
telomere length was determined (N = 1148). This was
followed by multivariable linear regression analysis of
the impact of randomisation to early PN or late PN, in
the subset of patients for whom neutrophil counts were
available (N = 644). This was necessary to allow adjust-
ment for the change in neutrophil fraction from admis-
sion to last PICU day, given that neutrophils have
shorter telomeres than lymphocytes [22, 23]. This multi-
variable linear regression analysis of the impact of ran-
domisation to early PN or late PN was further adjusted
for (a) other determinants of telomere length, being age
(as telomeres shorten with age) [21], gender (with shorter
telomeres expected for boys [20]) and the telomere length
upon admission, (b) the acute critical-illness-related base-
line risk factors, being the admission diagnosis, the degree
of organ failure (Paediatric Logistic Organ Dysfunction
(PeLOD) score), the estimated risk of death (Paediatric
Index of Mortality 2 (PIM2) score), the risk of malnutri-
tion (Screening Tool for Risk on Nutritional Status and
Growth (STRONGkids) risk group), whether or not there
was an infection present upon admission and the treat-
ment centre and (c) for markers of pre-existing chronic
disease (height and weight as percentiles of population
norms) and “chronicity” as a dichotomised label indicating
whether or not the patient was suffering from any symp-
tomatic chronic disease identified via screening of the
medical history and hospital files (Additional file 1), with
telomeres expected to be shorter in patients with chronic
illnesses [7, 10, 11, 20, 24]. To also investigate whether
any impact of early PN versus late PN on telomere length
change over time in PICU could be mediated by its nega-
tive effect on time to recovery, the multivariable linear re-
gression analysis of the impact of randomisation to early
PN or late PN was further adjusted for the duration of
PICU stay. Finally, as a sensitivity analysis, we further
adjusted the model for post-randomisation factors affected
by early versus late PN that could potentially be associated
with telomere length attrition. These included exposure to
higher cumulative doses of insulin and a higher risk of
developing new infections during the course of PICU stay
[2, 6, 25]. Given the collinearity between PICU duration of
stay and these post-randomisation effects of early PN, the
PICU stay was replaced by these factors in the model.
Statistical analyses were performed with JMP®12.0.0
(SAS Institute, Inc., Cary, NC, USA). Two-sided P values
of 0.05 or lower were considered statistically significant.
No corrections for multiple comparisons were done.
Results
The propensity-score matched comparison revealed that
median (IQR) leukocyte telomere length in critically ill
children upon PICU admission (1.625 (1.446–1.825))
was 6% shorter than that in healthy children (1.727
(1.547–1.915)) (P < 0.0001).
The patients in the early PN and late PN groups had
comparable baseline characteristics (Additional file 1:
Tables S1 and S2). The amount of nutrition given to
patients in the early PN and late PN groups is depicted
in Fig. 2.
We first assessed the impact of the randomised nutri-
tional management on the change in telomere length
during PICU stay in a univariate analysis. The change in
overall leukocyte telomere length from PICU admission to-
wards PICU discharge was significantly different between
patients randomised to early PN and patients randomised
to late PN (P = 0.03) (Fig. 3a). Indeed, whereas an apparent
increase was observed in patients randomised to late PN,
this rise was abolished by early PN. Importantly, neutro-
phils are known to have shorter telomeres than lympho-
cytes [22, 23], which could confound the analysis if the
neutrophil fraction changed within the same time window.
The neutrophil fraction decreased from PICU admission to
discharge in both groups, but even more in the early PN
than in the late PN group (P = 0.007) (Fig. 3b). Thus, the
leukocyte pool in patients receiving early PN relatively
shifted towards a population containing fewer cells, which
under baseline conditions would have shorter telomeres
(i.e. neutrophils) as compared with late PN. In combin-
ation, these findings suggest that early PN actually short-
ened leukocyte telomeres during PICU stay as compared
with late PN.
As several other factors, apart from the leukocyte compos-
ition, have been identified that could determine telomere
length and hence could introduce bias, we subsequently
investigated the impact of early PN versus late PN on the
change in telomere length from admission to the last day in
the PICU, adjusted for these factors in multivariable
regression analyses. Also when fully adjusting for po-
tential baseline confounders and change in neutrophil
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fraction (see “Methods”), early PN was significantly associ-
ated with shortened telomeres during the time in the PICU
as compared with late PN (estimate for early PN versus
late PN –0.021 T/S units, 95% CI –0.038; –0.004, P =
0.01) (Table 2, A; Fig. 3c). The effect size of the shortening
of telomere length by early PN with 0.021 T/S units repre-
sents 1.1% of the telomere length in the healthy children.
Other independent determinants of change in telomere
length identified in this model were age, gender, baseline
telomere length and fraction of neutrophils in the sample
from which the DNA was extracted (Table 2, A).
Further adjusting the model for duration of PICU stay
revealed that the telomere-shortening effect of early PN
was largely independent of its impact on time to recovery.
Indeed, although a longer PICU stay was associated with
telomere shortening (estimate per day in PICU –0.144 T/S
units, 95% CI −0.284; –0.004, P = 0.04), the use of early PN
remained independently associated with shortened telo-
meres on the last PICU day (estimate of early PN versus
late PN –0.020 T/S units, 95% CI −0.037; –0.003, P = 0.01)
in this model, as did age, baseline telomere length, and
change in fraction of neutrophils (Table 2, B).
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Fig. 2 Daily caloric intake of patients in the early parental nutrition (PN) and late PN groups. The total caloric intake per day of patients in the
early and late PN groups was calculated for the first week in the paediatric ICU (PICU) for the total number of patients for whom leukocyte
telomere length was determined (N = 1148) (a), and for the subset of patients for whom neutrophil counts were available (N = 644) (b), with N
indicating the number of patients for whom these data were available. Data are presented as mean and standard error of the mean (SEM). d, day;
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Finally, the sensitivity analysis, in which we further cor-
rected the multivariable analysis for post-randomisation
factors affected by early versus late PN, confirmed the ro-
bustness of the initial findings (Table 2, C). Indeed, early
initiation of PN remained independently associated with
telomere length attrition (estimate of early PN versus late
PN –0.018 T/S units, 95% CI −0.035; –0.0001, P = 0.04),
together with age, gender, baseline telomere length, and
change in fraction of neutrophils, whereas the amount of
insulin given and the acquisition of a new infection in
PICU were not related to the change in telomere length.
Discussion
Critically ill children presented to the PICU with signifi-
cantly shorter leukocyte telomeres than matched healthy
children. More importantly, early initiation of PN during
critical illness, as compared with postponing PN to be-
yond the first week in PICU, was associated with short-
ened leukocyte telomeres between PICU admission and
discharge. The telomere-shortening effect of early PN was
a robust finding, as it was maintained after adjustment for
other risk factors. Independent of the telomere-shortening
effect of early PN, children with a longer duration of stay
in the PICU also had shortened leukocyte telomere length
at PICU discharge.
In line with studies showing that children suffering
from chronic illnesses have shorter telomeres than
healthy peers [10, 11], we found that critically ill chil-
dren have shorter leukocyte telomeres upon admission
to the PICU than matched controls. In theory, this could
(partly) be explained by underlying chronic diseases hall-
marked by hypoxemia or inflammation, which could
predispose to adverse outcomes, by previous hospital
admissions or by unknown differences in environmental
exposures [12, 26]. Indeed, 82.6% of the patients in our
study cohort suffered from chronic comorbidity. In
addition, another partial explanation for the shorter telo-
meres upon PICU admission could be the acute rise in
the fraction of neutrophils within the white blood cell
population of critically ill patients, as neutrophils have
shorter telomeres than lymphocytes [27, 28].
The observed 6% shorter telomeres in patients admit-
ted to PICU represents a large difference with healthy
children. Indeed, in other paediatric settings, differ-
ences of only 0.5–4% have been reported [9–11]. For
example, in children with alpha1-antitrypsin deficiency,
2% shorter leukocyte telomeres have been related to
high levels of the oxidative stress biomarkers, malonyl-
dialdehyde, 8-hydroxydeoxyguanosine and H2O2 [10].
Furthermore, 4% shorter telomeres have been reported
in adolescents who were born extremely premature,
and this was found to be related to the respiratory dys-
function in these children [11]. This may suggest that
even small differences in telomere length may poten-
tially lead to clinically relevant alterations in phenotype.
The early use of PN, as compared with not using PN and
accepting a large macronutrient deficit that often occurs
when only relying on enteral feeding during the first week
in PICU, was found to further shorten telomeres from
PICU admission to discharge. This effect also remained ro-
bust after adjustment for potential confounders comprising,
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among other risk factors, type and severity of illness, admis-
sion telomere length and change in neutrophil fraction.
The effect size of the early PN-induced telomere shortening
determined in the adjusted model represented 1.1% of the
normal telomere length, which, although smaller than the
difference between patients and healthy children, was still
in the order of magnitude evoked by other environmental
factors [15, 29]. The early PN effect extended beyond its
negative impact on intensive care dependency, as both use
of early PN and longer PICU stay were independently asso-
ciated with telomere shortening from PICU admission to
discharge. The early PN effect on telomere length was also
independent of other post-randomisation factors affected
by early PN, including the larger amount of insulin given
and the higher risk of acquiring a new infection in the
PICU. A telomere shortening effect of early PN is in line
with the results from previous studies in rats that showed
slower telomere shortening with caloric restriction than
with ad libitum feeding [14]. Also large population-based
human studies showed that caloric restriction and better
adherence to a healthy diet were independently associated
with better preserved telomere length over time [15, 30].
The mechanisms explaining attenuation of telomere attri-
tion via caloric restriction remain speculative, but have
been suggested to involve anti-oxidative, anti-inflammatory
or other stress-mediated pathways [6, 15]. Also, autophagy
could be involved. Indeed, autophagy preserves the regen-
erative capacity of stem cells [31] and caloric restriction is
a powerful activator of autophagy [32]. Furthermore,
pharmacological autophagy activation has shown to induce
telomerase activity [33].
In line with previous reports in non-critically ill patients
we found that, besides early initiation of PN and duration
of critical illness, age, male gender and initial telomere
length are also determining factors of telomere length
shortening (Table 2-B). Indeed, in most somatic cells telo-
mere length declines with age, with a most pronounced loss
during early life, which can be explained by steady prolifera-
tion of stem cells and immune cells after birth [21]. After
infancy, a deceleration in telomere attrition is observed,
most likely reflecting an intrinsic, ontogeny-related change
in stem cell turnover and function. Furthermore, illnesses
of all kind have also repeatedly been associated with more
cell replication cycles in immune cells, which could further
shorten telomeres [10, 12]. With regard to gender, the exist-
ing evidence is consistent in reporting longer leukocyte
telomeres in women than in men [20, 34]. This has been at-
tributed to a slower rate of telomere attrition in women,
possibly due to higher oestrogen levels leading to more
optimal metabolising of reactive oxygen species [35]. In
contrast to previous studies in the setting of diabetes melli-
tus and infectious disease [25, 36, 37], the amount of insulin
given and the acquisition of a new infection were not inde-
pendently associated with telomere shortening in our study.
Shorter telomeres have been associated with long-term
health issues, such as poor lung function, risk of cancer, cog-
nitive decline and poor metabolic health [11, 12, 38–40].
Children who have been treated in intensive care suffer from
a substantial long-term legacy of that critical illness, charac-
terised by a physical and neurocognitive developmental im-
pairment, as documented 4–7 years after PICU admission
[3, 41]. The shorter telomeres upon PICU admission could
suggest that part of this long-term legacy is explained by
their risk profile upon admission. However, as the duration
of PICU stay and the use of early PN were found to be
associated with further telomere shortening, one could
hypothesise that the stress of the illness and/or the treat-
ments in PICU could add to the long-term legacy. Cur-
rently, involvement of accelerated telomere attrition in that
long-term legacy has not been investigated. However, the
telomere shortening effect of an extended PICU stay and of
early PN administration could in theory consume part of
the “telomeric reserve” of these children, which could make
them prone to chronic conditions such as asthma, recurrent
and/or chronic viral infections and neurocognitive impair-
ment [11, 39, 42]. Hence, identifying measures to attenuate
telomere shortening in PICU could potentially bring about
important long-term benefit to the children. As our study
suggests an iatrogenic telomere shortening effect of early
PN and thus potential long-term harm, while the PEPaNIC
study has shown lack of short-term benefit with an actual
increased risk of new infection and delayed recovery with
early PN [2], this may further support withholding of early
PN in critically ill children. However, the results of an on-
going, extensive medical and neurocognitive long-term
follow up of the PEPaNIC study cohort are awaited, which
will allow investigation of the actual clinical relevance of the
observed telomere shortening with longer PICU stays and
with the use of early PN, as a biomarker or a mediator of
susceptibility to long-term adverse outcomes after paediatric
critical illnesses.
The strengths of this study comprise the multicentre set-
ting of the PEPaNIC randomized controlled trial, the large
group of healthy children and the paired measurements
per patient allowing documentation of leukocyte telomere
length dynamics from PICU admission to discharge within
the same child. Importantly, the telomere shortening effect
of early PN was found in the context of a large randomised
controlled study design and could be confirmed after full
adjustment for known potential confounders.
Some limitations should also be considered. Indeed,
leukocyte composition was only available in a subgroup of
patients and did not differentiate between e.g. lymphocyte
subtypes. However, the subpopulation of patients in whom
neutrophil counts were available was large and representa-
tive of the total population. Also, although we identified
factors that may contribute to accelerated telomere short-
ening during the course of the PICU stay, the long-term
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outcome of these children should be documented to
investigate whether shorter telomeres partially explain the
observed legacy following paediatric critical illness.
Conclusions
Shorter-than-normal leukocyte telomeres were observed in
children upon PICU admission. Strikingly, early initiation
of PN during critical illness and an extended duration of
PICU stay further shortened leukocyte telomeres between
PICU admission and discharge. Whether this predisposes
to long-term consequences of paediatric critical illness and
“unhealthy ageing” remains to be investigated in a pro-
spective follow-up study.
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